Journal profile · ONCOLOGY
Breast Cancer-Targets and Therapy
ISSN 1179-1314 · Dove Medical Press · United Kingdom
Breast Cancer-Targets and Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.61; JCR Q2 (journal website); fully open access; APC about USD 4,320; median 95 days to acceptance (104 articles, last 24 months); acceptance rate 28% (journal website); 104 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Breast Cancer-Targets and Therapy is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research and Advanced Breast Cancer Therapies, together about 36.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Pranela Rameshwar Breast Cancer: Targets and Therapy is an international, peer reviewed, open access journal that publishes basic and translational studies, as well as clinical trials on breast cancer. The journal encourages original and review articles on breast cancer treatment. The latter includes outcome studies that incorporate preventative and integrated treatment strategies that enhance survival, and quality of life for cancer patients. The journal’s audience includes medical oncologists, physicians and basic scientists, radiation oncologists, surgical oncologists, nurses, patient navigators, policymakers, and healthcare professionals interested in the prevention, diagnosis, and treatment of breast cancer. Specific topics covered in the journal include: Epidemiology, detection and screening Male breast cancer Cellular research and biomarkers Cancer stem cells Cancer dormancy and metastasis Novel biotargets and other agents such as small non-coding RNA Drug Delivery Systems Optimal clinical use of existing anti-cancer agents, including combination therapies Radiation and surgery Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations Genetic and epigenetic mechanisms Hormone-mediated breast cancer Premature aging and breast cancer The journal welcomes submitted papers on the above and related topics and breast cancer, treatment guidelines, expert opinion and commentaries. Breast Cancer: Targets and Therapy will no longer consider: meta-analyses bibliometric analyses or case report/series When considering submission of a paper utilizing publicly available data (e.g. SEER/GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about breast cancer or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Updated 25 November 2025
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Pranela RameshwarPublisher website
Editorial board by country: 2 in mainland China (about 3%); most named United States 64, India 3, Mainland China 2, Spain 2, Egypt 2 (74 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology19.4%
- HER2/EGFR in Cancer ResearchMedicine9.6%
- Advanced Breast Cancer TherapiesMedicine7.5%
- Breast Lesions and CarcinomasMedicine6.7%
- Cancer Treatment and PharmacologyMedicine4.6%
- Global Cancer Incidence and ScreeningMedicine4.6%
- Cancer Cells and MetastasisMedicine4%
- Cancer Risks and FactorsMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.61LetPub ·
- Impact factor (publisher) 2025
- 3.9Publisher website ·
- 5-year impact factor (publisher)
- 5Publisher website ·
- CiteScore 2026-06
- 5LetPub ·
- CiteScore (publisher) 2025
- 0.96Publisher website ·
- SJR 2026-06
- 0.99LetPub ·
- SNIP 2026-06
- 0.96LetPub ·
- h-index
- 54OpenAlex ·
- i10-index
- 315OpenAlex ·
- 2-year mean citedness
- 2.02OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.6%LetPub ·
Volume
- Articles per year
- 101LetPub ·
- Downloads per year (publisher)
- 114,032Publisher website ·
Articles by year OpenAlex count · 763 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 111 | 111 | 29 |
| 2025 | 104 | 104 | 297 |
| 2024 | 76 | 76 | 261 |
| 2023 | 79 | 79 | 892 |
| 2022 | 41 | 41 | 648 |
| 2021 | 58 | 58 | 1,041 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
95 daysMedian, submission to acceptance · P25–P75 70 days – 124 days
- Acceptance to online
- median 14 days (104 articles)
- Submission to online
- median 113 days
- Sample
- 104 articles with submission and acceptance dates (239 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 28%Publisher website ·
- Desk decision
- 39 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,320 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 3,300 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review
- Publication ethics
Member of and subscribes to the principles of the Committee on Publication Ethics (COPE) Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- Peer review
Offers Accelerated Publication Model summary
This journal offers Accelerated Publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1179-1314
- Official links
- Journal homepage ↗OpenAlex
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Breast Cancer-Targets and Therapy
What CAS zone is Breast Cancer-Targets and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Breast Cancer-Targets and Therapy is in Zone 3 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Breast Cancer-Targets and Therapy?
The latest impact factor listed by LetPub is 3.61; CiteScore 5, h-index 54.
How long does peer review take at Breast Cancer-Targets and Therapy?
Based on the dates recorded on 104 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 95 days (interquartile range 70–124 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 28%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Breast Cancer-Targets and Therapy in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Breast Cancer-Targets and Therapy based?
Of the 74 board members whose country the journal's board page names, 2 (about 3%) are in mainland China; the countries named most often are United States (64), India (3) and Mainland China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Breast Cancer-Targets and Therapy?
According to LetPub and DOAJ records, Breast Cancer-Targets and Therapy is indexed in SCIE, Scopus and DOAJ.
Is Breast Cancer-Targets and Therapy open access, and what is the APC?
Breast Cancer-Targets and Therapy is a fully open-access journal. APC about USD 4,320.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .